Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2009-10-19
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes
NCT02540733
Functional MRI Biomarkers of Cognitive Decrements in Diabetes
NCT01705210
Natural History of Multiple Sclerosis and Its Mimickers
NCT02504840
Relationship and Central Mechanism Between Diabetes and Cognitive Impairment Based on Simultaneous EEG-fMRI Approach and Peripheral Neuropathology Biomarkers Assay
NCT05545657
Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism
NCT02059733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
TRIAL OBJECTIVES AND PURPOSE Specific Aim 1: To study the biophysical properties of the white and gray matter in critical cortical and subcortical regions using magnetization transfer in patients with type 2 diabetes and MDD, non-depressed diabetic controls, patients with unipolar depression without diabetes and nondiabetic healthy controls. The investigators are interested in the separate and cumulative effects of both diabetes and depression on Magnetization Transfer Ratios (MTR) in different brain regions.
Hypothesis: The overarching hypothesis is that both diabetes and depression have the effect of lowering magnetization transfer ratios (MTR) in the anterior cingulate cortex, subcortical nuclei (head of the caudate nucleus and putamen) and the frontal white matter. These effects are cumulative and may not be additive in some regions. Our pilot data suggest that MTR will be lower in these regions in patients with type 2 diabetes (both with and without depression) when compared with healthy controls. In some regions (eg. head of the caudate nucleus - see preliminary data) the investigators anticipate that patients with diabetes and MDD will have the lowest and healthy controls will have the highest MT ratios. The group with unipolar depression without diabetes and the diabetic controls will have MT ratios that fall between these two groups. In other regions of interest, both groups with diabetes will have values significantly different from healthy controls, with patients diagnosed with unipolar depression falling between the healthy and diabetic groups.
Specific Aim 2: To examine levels of glutamate and aspartate (creatine ratios) in two regions involved in the regulation of mood and cognition - the bilateral anterior cingulate cortex and the left subcortical region (the head of the caudate nucleus and the putamen) in patients with type 2 diabetes and our three comparison groups.
Hypothesis: Levels of glutamate and aspartate (creatine ratios) will be lower in patients with combined Type 2 Diabetes and MDD when compared with non-depressed diabetic patients and healthy controls. Our pilot data provide little basis to expect a simple effect of diabetes alone but do not rule out an interaction such that effects are only seen, or are worsened, by the combination of diabetes and depression. The inclusion of a depressed non-diabetic group in the current design will make it possible to evaluate whether the observed effect in the doubly-diagnosed group is best viewed as an effect of depression alone or as an interaction in which diabetes plays a role.
Specific Aim 3: To examine the relationship between regional MTRs and specific cognitive domains in subjects in all four groups.
Hypothesis: There will be direct correlations in all study groups between MT ratios in the subcortical nuclei, anterior cingulate cortex and the dorsolateral white matter and performance on specific cognitive domains, including attention, executive functions, learning and memory and psychomotor processing.
Exploratory Aim 1: In an exploratory manner the investigators will estimate cerebral blood volume, a measure of the cerebral microvasculature, in critical brain regions involved in frontal-subcortical circuitry (anterior cingulate, dorsolateral white, head of the caudate nucleus and the putamen) in subjects in our depressed diabetic group and the three comparison groups using dynamic susceptibility contrast MR imaging (perfusion-weighted MR imaging).
Exploratory Aim 2: A comparison of blood samples from healthy controls, diabetic subjects, depressed subjects and subjects with both depression and diabetes to see if there is evidence of differences in plasma neurotransmitter levels, hypothalamic-pituitary-adrenals (HPA) axis, and immune function between these four subject groups
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depressed
Patients with Major Depressive Disorder
No interventions assigned to this group
Diabetic
Patients with Type 2 Diabetes
No interventions assigned to this group
Diabetic/Depressed
Patients with both diabetes and major depressive disorder
No interventions assigned to this group
Healthy Controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of type 2 diabetes
* Diagnosis of major depressive disorder using standard diagnostic and statistical manual (DSM) criteria
* Score of 15 or greater on the 17-item Hamilton Depression rating scale
* Mini Mental Status Exam score of 24 or greater
* No evidence of clinical dementia or any other clinical brain disorder
* Free of psychotropic/psychoactive medications for at least 2 weeks
* First episode of depression diagnosed either after or around the time type 2 diabetes was diagnosed since we are interested in the relationship between the cerebrovascular effect of diabetes and the pathophysiology of major depression
Exclusion Criteria
* Mini Mental Status Exam score of less than 24
* Unstable medical illness (grade 4 on the Cumulative Illness Rating Scale)
* Presence of any metallic implant that would preclude an MRI scan (pacemaker, etc.)
* Concurrent Axis 1 disorder (schizophrenia, bipolar)
* Use of atypical neuroleptics for the current episode and/or strong clinical suspicion that the diabetes is secondary to the use of atypical neuroleptics;
* Recurrent major depression, operationally defined as two or more, well-characterized episodes of depression, prior to the onset/diagnosis of diabetes
* Seizure disorder
* Stroke/Transient Ischemic Attack
* Central nervous system disorder (multiple sclerosis)
* Trauma to head/Loss of Consciousness
* Claustrophobia
* Eating disorder (anorexia, bulimia)
* Weight of over 350 pounds
* Learning disorder (dyslexia, ADHD)
* Psychosis, panic or anxiety disorder outside the context of depression
* Pregnancy
30 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of Illinois at Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anand Kumar, MD
Role: PRINCIPAL_INVESTIGATOR
University of Illinois at Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Illinois
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ajilore O, Narr K, Rosenthal J, Pham D, Hamilton L, Watari K, Elderkin-Thompson V, Darwin C, Toga A, Kumar A. Regional cortical gray matter thickness differences associated with type 2 diabetes and major depression. Psychiatry Res. 2010 Nov 30;184(2):63-70. doi: 10.1016/j.pscychresns.2010.07.003. Epub 2010 Sep 15.
Nguyen TT, Wong TY, Islam FM, Hubbard L, Ajilore O, Haroon E, Darwin C, Esser B, Kumar A. Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression. Psychosom Med. 2010 Jul;72(6):535-8. doi: 10.1097/PSY.0b013e3181da90f4. Epub 2010 Apr 5.
Kumar A, Gupta R, Thomas A, Ajilore O, Hellemann G. Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression. Arch Gen Psychiatry. 2009 Mar;66(3):324-30. doi: 10.1001/archgenpsychiatry.2008.548.
Watari K, Elderkin-Thompson V, Ajilore O, Haroon E, Darwin C, Pham D, Kumar A. Neuroanatomical correlates of executive functioning in depressed adults with type 2 diabetes. J Clin Exp Neuropsychol. 2008 May;30(4):389-97. doi: 10.1080/13803390701440486.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-0473
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.